前列癃閉通片聯(lián)合坦洛新膠囊治療腎虛血瘀型BPH的臨床研究
發(fā)布時(shí)間：2018-09-04 07:45
【摘要】：背景：良性前列腺增生癥(Benign Prostatic Hyperplasia, BPH)是中老年男性的多發(fā)病、常見病,其發(fā)病率隨人口壽命的延長、生活水平的提高而逐年增加。50-60歲男性一般有50%出現(xiàn)病理上前列腺肥大,80歲時(shí)可高達(dá)90%以上。前列腺肥大可以壓迫尿道,使尿道狹窄,出現(xiàn)排尿困難、尿不盡,嚴(yán)重者出現(xiàn)尿潴留,如梗阻時(shí)間過長可導(dǎo)致腎功能損害,甚至危及生命；BPH已成為國際上關(guān)注的重大疾病。前列腺增生屬于中醫(yī)學(xué)上的“癃閉”、“精癃”的范疇。本研究小組立足于臨床結(jié)合理論,采用前列癃閉通片聯(lián)合坦洛新膠囊治療腎虛血瘀型良性前列腺增生癥,在改善患者排尿癥狀、提高生活質(zhì)量等方面取得了顯著的療效。目的：研究前列癃閉通片聯(lián)合坦洛新膠囊治療腎虛血瘀型BPH的臨床療效及安全性。方法：采用隨機(jī)、對(duì)照的臨床研究方法,選取良性前列腺增生癥(腎虛血瘀型)患者87例,分為2組,即治療組和對(duì)照組,治療組44例,對(duì)照組43例。治療組服用前列癃閉通片聯(lián)合坦洛新膠囊,對(duì)照組服用坦洛新膠囊。1個(gè)月為一個(gè)療程,共觀察3個(gè)療程。3個(gè)療程結(jié)束后,觀察兩組治療前后患者國際前列腺癥狀評(píng)分(I-PSS)、排尿癥狀對(duì)生活質(zhì)量(QOL)的影響、中醫(yī)癥狀評(píng)分、最大尿流率(MFR)、前列腺體積及殘余尿的變化。所有的結(jié)果均采用SPSS19.0統(tǒng)計(jì)分析軟件進(jìn)行統(tǒng)計(jì)分析,P0.05表示差異有統(tǒng)計(jì)學(xué)意義。結(jié)果：治療組42例病人中,治愈率21.88%、顯效率53.13%、有效率21.88%、無效率3.13%,總有效率96.87%；相比對(duì)照組42例病人,(治愈率6.25%、顯效率25%、有效率46.88%、無效率21.88%,總有效率78.12%),總有效率差異有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組在國際前列腺癥狀評(píng)分(I-PSS)、排尿癥狀對(duì)生活質(zhì)量(QOL)的影響、中醫(yī)證狀評(píng)分、最大尿流率(MFR)、殘余尿量(RUV)均較治療前有明顯改善,優(yōu)于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后前列腺體積相比,治療組對(duì)縮小前列腺體積有一定的作用(P0.05),而對(duì)照組對(duì)前列腺體積無明顯改變,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論：前列癃閉通片聯(lián)合坦洛新膠囊治療腎虛血瘀型良性前列腺增生癥臨床安全有效,能提高藥物治療的總有效率,減少IPSS積分,改善排尿癥狀對(duì)生活質(zhì)量的影響,提高患者的生活質(zhì)量,減少中醫(yī)癥狀評(píng)分,縮小前列腺體積,增加最大尿流率,減少殘余尿量,特別是能明顯改善患者的排尿癥狀；故可以作為治療該病的一種良好選擇。
[Abstract]:Background: benign prostatic hyperplasia (Benign Prostatic Hyperplasia, BPH) is a common disease in middle-aged and elderly men. 50% of males aged 50 to 60 years have pathological prostatic hypertrophy, which can reach more than 90% by the age of 80 years. Prostatic hypertrophy can compress urethra, make urethral stricture, dysuria, urine retention in severe cases, such as too long time of obstruction can lead to damage of renal function, even life-threatening BPH has become a major disease of international concern. Prostatic hyperplasia belongs to the traditional Chinese medicine "Longlongong", "Longlong" category. Based on the theory of clinical combination, the study group treated benign prostatic hyperplasia of kidney deficiency and blood stasis type with Qianlie Longboutong tablet and Tanluoxin capsule, and achieved remarkable curative effect in improving the urination symptoms and improving the quality of life of the patients. Objective: to study the clinical efficacy and safety of Qianlie Longboutong tablet combined with Tanluoxin capsule in the treatment of kidney deficiency and blood stasis type BPH. Methods: 87 patients with benign prostatic hyperplasia (kidney deficiency and blood stasis) were randomly divided into two groups: treatment group (n = 44) and control group (n = 43). The treatment group was treated with Qianlie Longboutong tablet combined with Tanluoxin capsule, and the control group was treated with tanluoxin capsule. One month was a course of treatment and three courses of treatment were observed. The changes of international prostate symptom score (I-PSS), the influence of urination symptoms on quality of life (QOL), traditional Chinese medicine (TCM) symptom score, maximum urinary flow rate (MFR),) and residual urine were observed before and after treatment. All the results were statistically significant using SPSS19.0 statistical analysis software. Results: in the treatment group, the cure rate was 21.88, the effective rate was 53.13, the effective rate was 21.88, the inefficiency was 3.13, the total effective rate was 96.87. Compared with 42 patients in the control group, the total effective rate was 78.12% and the total effective rate was 78.12%. The total effective rate was significantly higher than that of the control group (cure rate 6.25%, effective rate 256.88%, effective rate 46.88%, total effective rate 78.12%) (P0.05). The international prostatic symptom score (I-PSS), the effect of urination symptom on (QOL), TCM syndrome score and (RUV) of (MFR), residual urine volume in both groups were significantly improved compared with those before treatment, and the difference was statistically significant (P0.05). Compared with the prostate volume after treatment, the treatment group had a certain effect on reducing the prostate volume (P0.05), while the control group had no significant change in prostate volume, the difference was not statistically significant (P0.05). Conclusion: Qianlie Longboutong tablet combined with Tanluoxin capsule is safe and effective in the treatment of benign prostatic hyperplasia with kidney deficiency and blood stasis. It can improve the total effective rate of drug therapy, reduce the IPSS score, and improve the effect of urination symptoms on the quality of life. It can improve the quality of life of patients, reduce the score of TCM symptoms, reduce the volume of prostate, increase the maximum urine flow rate, reduce the residual urine volume, especially can obviously improve the urination symptoms of the patients, so it can be used as a good choice for the treatment of the disease.
【學(xué)位授予單位】：北京中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R697.3
本文編號(hào)：2221441
[Abstract]:Background: benign prostatic hyperplasia (Benign Prostatic Hyperplasia, BPH) is a common disease in middle-aged and elderly men. 50% of males aged 50 to 60 years have pathological prostatic hypertrophy, which can reach more than 90% by the age of 80 years. Prostatic hypertrophy can compress urethra, make urethral stricture, dysuria, urine retention in severe cases, such as too long time of obstruction can lead to damage of renal function, even life-threatening BPH has become a major disease of international concern. Prostatic hyperplasia belongs to the traditional Chinese medicine "Longlongong", "Longlong" category. Based on the theory of clinical combination, the study group treated benign prostatic hyperplasia of kidney deficiency and blood stasis type with Qianlie Longboutong tablet and Tanluoxin capsule, and achieved remarkable curative effect in improving the urination symptoms and improving the quality of life of the patients. Objective: to study the clinical efficacy and safety of Qianlie Longboutong tablet combined with Tanluoxin capsule in the treatment of kidney deficiency and blood stasis type BPH. Methods: 87 patients with benign prostatic hyperplasia (kidney deficiency and blood stasis) were randomly divided into two groups: treatment group (n = 44) and control group (n = 43). The treatment group was treated with Qianlie Longboutong tablet combined with Tanluoxin capsule, and the control group was treated with tanluoxin capsule. One month was a course of treatment and three courses of treatment were observed. The changes of international prostate symptom score (I-PSS), the influence of urination symptoms on quality of life (QOL), traditional Chinese medicine (TCM) symptom score, maximum urinary flow rate (MFR),) and residual urine were observed before and after treatment. All the results were statistically significant using SPSS19.0 statistical analysis software. Results: in the treatment group, the cure rate was 21.88, the effective rate was 53.13, the effective rate was 21.88, the inefficiency was 3.13, the total effective rate was 96.87. Compared with 42 patients in the control group, the total effective rate was 78.12% and the total effective rate was 78.12%. The total effective rate was significantly higher than that of the control group (cure rate 6.25%, effective rate 256.88%, effective rate 46.88%, total effective rate 78.12%) (P0.05). The international prostatic symptom score (I-PSS), the effect of urination symptom on (QOL), TCM syndrome score and (RUV) of (MFR), residual urine volume in both groups were significantly improved compared with those before treatment, and the difference was statistically significant (P0.05). Compared with the prostate volume after treatment, the treatment group had a certain effect on reducing the prostate volume (P0.05), while the control group had no significant change in prostate volume, the difference was not statistically significant (P0.05). Conclusion: Qianlie Longboutong tablet combined with Tanluoxin capsule is safe and effective in the treatment of benign prostatic hyperplasia with kidney deficiency and blood stasis. It can improve the total effective rate of drug therapy, reduce the IPSS score, and improve the effect of urination symptoms on the quality of life. It can improve the quality of life of patients, reduce the score of TCM symptoms, reduce the volume of prostate, increase the maximum urine flow rate, reduce the residual urine volume, especially can obviously improve the urination symptoms of the patients, so it can be used as a good choice for the treatment of the disease.
【學(xué)位授予單位】：北京中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R697.3
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 何政遠(yuǎn);;加味補(bǔ)中益氣湯治療前列腺增生60例[J];成都中醫(yī)藥大學(xué)學(xué)報(bào);2006年04期
2 王夢(mèng)芝;;良性前列腺增生癥的藥物治療進(jìn)展[J];當(dāng)代醫(yī)學(xué);2010年14期
3 史靜t$;良性前列腺增生癥患者生活質(zhì)量研究進(jìn)展[J];中國醫(yī)師雜志;2003年06期
4 孫雨良;生活質(zhì)量作為腫瘤外科的結(jié)局評(píng)估(編譯)[J];國外醫(yī)學(xué).外科學(xué)分冊(cè);2002年01期
5 歐春;加味五苓散治療前列腺增生癥臨床觀察[J];廣西中醫(yī)藥;1997年05期
6 徐澤杰;中藥內(nèi)服外敷治療前列腺增生癥82例[J];湖北中醫(yī)雜志;2003年03期
7 黃移生;陳敏;龔玉林;彭易雨;;秩邊穴齊刺為主治療良性前列腺增生癥療效觀察[J];湖北中醫(yī)雜志;2010年09期
8 徐浩;毛紅蓉;;溫針灸治療良性前列腺增生癥療效觀察[J];湖北中醫(yī)雜志;2011年03期
9 史靜t$,蔡太生,彭敏寧,孫振球;良性前列腺增生癥患者專用生活質(zhì)量量表的編制[J];中南大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2005年01期
10 韓燕;中藥黃芪的研究概況[J];河南中醫(yī)學(xué)院學(xué)報(bào);2003年06期
相關(guān)會(huì)議論文 前1條
1 于力;;中藥小金丸治療良性前列腺增生的臨床觀察[A];第十五屆全國泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年
，本文編號(hào)：2221441
本文鏈接：http://www.lk138.cn/yixuelunwen/mjlw/2221441.html
最近更新
教材專著
